Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Working Capital Changes (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Working Capital Changes for 4 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 63.91% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.5 million through Dec 2025, down 171.86% year-over-year, with the annual reading at -$5.5 million for FY2025, 171.86% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.1 million at Phathom Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $5.9 million in Q4 2024, with the low at -$7.8 million in Q1 2025.
  • Average Other Working Capital Changes over 4 years is $755375.0, with a median of $909000.0 recorded in 2023.
  • The sharpest move saw Other Working Capital Changes surged 2218.11% in 2024, then tumbled 1647.2% in 2025.
  • Over 4 years, Other Working Capital Changes stood at $4.2 million in 2022, then crashed by 93.88% to $254000.0 in 2023, then soared by 2218.11% to $5.9 million in 2024, then plummeted by 63.91% to $2.1 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $2.1 million, -$1.4 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.